Ozanimod 230microgram capsules
Requires a prescription from a doctor or prescriber
Ozanimod is a once-daily sphingosine 1-phosphate receptor modulator for the treatment of relapsing Multiple Sclerosis (MS) and inflammatory bowel disease.
Official documents, adverse reaction reporting, and safety monitoring
Report a side effect
Submit a Yellow Card report to the MHRA
Safety monitoring data
Yellow Card reports
The MHRA Yellow Card scheme collects reports of suspected side effects from healthcare professionals and patients. View the Drug Analysis Profile (iDAP) for real-world adverse reaction data.
View Drug Analysis Profile
Suspected adverse reactions reported for Ozanimod
Browse all iDAP reports
Interactive Drug Analysis Profiles for all medicines
Report a side effect
Submit a Yellow Card report to the MHRA
Data from the MHRA Yellow Card scheme. A reported reaction does not necessarily mean the medicine caused it. Contains public sector information licensed under the Open Government Licence v3.0.
EudraVigilance
The European Medicines Agency (EMA) collects suspected adverse reaction reports from across the EU/EEA through the EudraVigilance system. Search for safety data on this medicine.
View EudraVigilance report
Suspected adverse reactions reported for Ozanimod
About EudraVigilance
Learn about EU pharmacovigilance and safety monitoring
EudraVigilance data is published by the European Medicines Agency (EMA). A suspected adverse reaction is not necessarily caused by the medicine.
1 branded products available
MHRA licensed products
View all licensed products for Ozanimod on the MHRA register
Zeposia 0.23mg capsules
WHO defined daily dose (DDD)
920 microgram
Not a recommended dose. The DDD is the assumed average maintenance dose per day for a drug used for its main indication in adults. It is a statistical measure used for research and comparison purposes only.
Source: WHO Collaborating Centre for Drug Statistics Methodology, distributed via NHS dm+d BNF mapping files. Contains public sector information licensed under the Open Government Licence v3.0.
Therapeutically similar medicines
Similarity based on WHO Anatomical Therapeutic Chemical (ATC) classification and NHS BNF section grouping. Source data: NHS dm+d via TRUD (OGL v3.0), WHO ATC/DDD Index.
Clinical guidelines and formulary information
British National Formulary
Ozanimod
Source: British National Formulary, NICE. Joint Formulary Committee. Contains public sector information licensed under the Open Government Licence v3.0.
NICE clinical guidance(6)
Ozanimod for treating relapsing–remitting multiple sclerosis (TA706)
Ozanimod for treating moderately to severely active ulcerative colitis (TA828)
Upadacitinib for treating moderately to severely active ulcerative colitis (TA856)
Ulcerative colitis: management (NG130)
Ponesimod for treating relapsing–remitting multiple sclerosis (TA767)
Multiple sclerosis in adults: management (NG220)
Source: National Institute for Health and Care Excellence (NICE). Contains public sector information licensed under the Open Government Licence v3.0.
Check stock at pharmacies and supply information
Pharmacy stock checkers
Search for this medicine at major UK pharmacy chains. These links open the retailer's own website — results depend on their current online catalogue.
Supply & product information
Official product databases and supply status monitoring
Pharmacy links redirect to the retailer's own search and do not represent real-time stock levels. emc (electronic medicines compendium) is operated by Datapharm Ltd. Shortage information sourced from NHS Specialist Pharmacy Service (SPS), sps.nhs.uk.
Codes for healthcare professionals and prescribing systems
These codes are used by healthcare IT systems and prescribers to identify this medicine.
NHS UK identifiers
Browse tools
SNOMED CT and dm+d codes from NHS TRUD (Technology Reference data Update Distribution), licensed under the Open Government Licence v3.0. BNF codes from NHS Business Services Authority (NHSBSA). ATC codes from the WHO Collaborating Centre for Drug Statistics Methodology (whocc.no).
Active and completed clinical studies from ClinicalTrials.gov
Source: ClinicalTrials.gov, a database of the U.S. National Library of Medicine (NLM), National Institutes of Health (NIH). Data accessed via ClinicalTrials.gov API v2. Trial information is provided for research purposes and does not constitute medical advice.
Pharmacology and chemical data from DrugBank
Key facts
Drug status
Approved
Major interactions
None known
Half-life
17-21 hours
Mechanism
Sphingosine‐1‐phosphate (S1P) is an important phospholipid that binds to various…
Food interactions
2 warnings
Human targets
2 targets
Data: DrugBank · CC BY-NC 4.0
Pharmacokinetics at a glance
Absorption
0.244 ng/mL
Half-life
17-21 hours
[A189321][A192744][L12582]
Protein binding
98%
[L12582]
Volume of distribution
5590L
[L12582]
Another reference mentions a volume of distribution ranging from 73-101 L/kg.
[A189321]…
Metabolism
6%
Elimination
0.92 mg
[A189321]…
Clearance
192 L/h
[L12582]…
Pharmacokinetic data: DrugBank · CC BY-NC 4.0
MS is a devastating inflammatory disease that often progresses and causes severe neurological, physical, and cognitive effects.[A176474] Inflammatory bowel disease also a chronic inflammatory condition and can cause persistent abdominal pain, diarrhea, bloody stools, and vomiting.[A189336]
In clinical trials, Ozanimod has been shown to be well-tolerated and has resulted in a higher decrease in the rate of MS relapses than with intramuscular [interferon beta-1a], a current standard in MS therapy. Studies involving patients with inflammatory bowel disease have also shown promising results.[A189318][A189342]
[L12582][L39382][L41524]
Known interactions with other medications. Always consult a healthcare professional.
Showing 50 of 620 interactions
[A189321][A192747][L12582]
The NOAEL dose is 0.164 mg/kg/d for monkeys, and the human equivalent dose to this is about 0.053 mg/kg/day.
[A189321]
An overdose of this drug likely results in adverse effects such as somnolence, fatigue, headache, dizziness, bradyarrhythmia, cardiac conduction defects, hypertension, liver injury, and nausea.
[A189321][L12582]
Ozanimod is a selective modulator of S1P receptors and binds to S1P1R and S1P5R subtypes.[A189333] The mechanism of action of ozanimod is not fully understood, but this drug likely reduces the migration of lymphocytes that usually aggravate the inflammation associated with MS.[L12582]
How the body processes this drug — absorption, distribution, metabolism, and elimination
[L12582]
Its delayed absorption reduces effects that may occur after the first dose, such as heart rate changes.
The peak plasma concentration of ozanimod is low due to a high volume of distribution.
[A192744]
[A189321][A192744][L12582]
[L12582]
[L12582]
Another reference mentions a volume of distribution ranging from 73-101 L/kg.
[A189321]
This drug crosses the blood-brain barrier.
[A192744]
[L12582]
[A189321]
After a 0.92 mg dose of radiolabeled ozanimod was administered, about 26% of the labeled drug was accounted for in the urine and 37 % in the feces, mainly in the form of inactive metabolites.
[L12582]
[L12582]
Another reference indicates an oral clearance of 233 L/h.
[A189321]
Proteins and enzymes this drug interacts with in the body
Required for normal chemotaxis toward sphingosine 1-phosphate. Required for normal embryonic heart development and normal cardiac morphogenesis. Plays an important role in the regulation of sprouting angiogenesis and vascular maturation.
Inhibits sprouting angiogenesis to prevent excessive sprouting during blood vessel development. Required for normal egress of mature T-cells from the thymus into the blood stream and into peripheral lymphoid organs. Plays a role in the migration of osteoclast precursor cells, the regulation of bone mineralization and bone homeostasis (By similarity).
Plays a role in responses to oxidized 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine by pulmonary endothelial cells and in the protection against ventilator-induced lung injury
May play a regulatory role in the transformation of radial glial cells into astrocytes and may affect proliferative activity of these cells
Enzymes involved in drug metabolism — important for understanding drug interactions
Proteins that transport this drug across cell membranes
PMID:11049757 PMID:11134050 PMID:20493079 PMID:8316221 PMID:8665924
Preferentially degrades benzylamine and phenylethylamine PMID:11049757 PMID:11134050 PMID:20493079 PMID:8316221 PMID:8665924
PMID:11306452 PMID:12958161 PMID:19506252 PMID:20705604 PMID:28554189 PMID:30405239 PMID:31003562
Involved in porphyrin homeostasis, mediating the export of protoporphyrin IX (PPIX) from both mitochondria to cytosol and cytosol to extracellular space, it also functions in the cellular export of heme .
PMID:20705604 PMID:23189181
Also mediates the efflux of sphingosine-1-P from cells .
PMID:20110355
Acts as a urate exporter functioning in both renal and extrarenal urate excretion .
PMID:19506252 PMID:20368174 PMID:22132962 PMID:31003562 PMID:36749388
In kidney, it also functions as a physiological exporter of the uremic toxin indoxyl sulfate (By similarity). Also involved in the excretion of steroids like estrone 3-sulfate/E1S, 3beta-sulfooxy-androst-5-en-17-one/DHEAS, and other sulfate conjugates .
PMID:12682043 PMID:28554189 PMID:30405239
Mediates the secretion of the riboflavin and biotin vitamins into milk (By similarity). Extrudes pheophorbide a, a phototoxic porphyrin catabolite of chlorophyll, reducing its bioavailability (By similarity).
Plays an important role in the exclusion of xenobiotics from the brain (Probable). It confers to cells a resistance to multiple drugs and other xenobiotics including mitoxantrone, pheophorbide, camptothecin, methotrexate, azidothymidine, and the anthracyclines daunorubicin and doxorubicin, through the control of their efflux .
PMID:11306452 PMID:12477054 PMID:15670731 PMID:18056989 PMID:31254042
In placenta, it limits the penetration of drugs from the maternal plasma into the fetus (By similarity). May play a role in early stem cell self-renewal by blocking differentiation (By similarity).
In inflammatory macrophages, exports itaconate from the cytosol to the extracellular compartment and limits the activation of TFEB-dependent lysosome biogenesis involved in antibacterial innate immune response
PMID:2897240 PMID:35970996 PMID:8898203 PMID:9038218 PMID:35507548
Catalyzes the flop of phospholipids from the cytoplasmic to the exoplasmic leaflet of the apical membrane. Participates mainly to the flop of phosphatidylcholine, phosphatidylethanolamine, beta-D-glucosylceramides and sphingomyelins .
PMID:8898203
Energy-dependent efflux pump responsible for decreased drug accumulation in multidrug-resistant cells PMID:2897240 PMID:35970996 PMID:9038218
ATC L04AE02
Chemical identifiers
CAS, UNII, InChI Key and database cross-references
Show
Chemical identifiers
CAS, UNII, InChI Key and database cross-references
Linked compound data from DrugBank Open Data (CC BY-NC 4.0)
Ozanimod
Additional database identifiers
Drugs Product Database (DPD)
23516
ChemSpider
34979946
BindingDB
50507186
PDB
JEU
ZINC
ZINC000116109867
HUGO Gene Nomenclature Committee (HGNC)
HGNC:3165
GeneCards
S1PR1
Guide to Pharmacology
275
UniProt Accession
S1PR1_HUMAN
HUGO Gene Nomenclature Committee (HGNC)
HGNC:14299
GenAtlas
EDG8
GeneCards
S1PR5
GenBank Gene Database
AF331840
Guide to Pharmacology
279
UniProt Accession
S1PR5_HUMAN
HUGO Gene Nomenclature Committee (HGNC)
HGNC:403
GenAtlas
ALDH3A2
GeneCards
ALDH3A2
GenBank Gene Database
L47162
GenBank Protein Database
1082036
UniProt Accession
AL3A2_HUMAN
HUGO Gene Nomenclature Committee (HGNC)
HGNC:253
GenAtlas
ADH5
GeneCards
ADH5
GenBank Gene Database
M30471
GenBank Protein Database
178134
UniProt Accession
ADHX_HUMAN
HUGO Gene Nomenclature Committee (HGNC)
HGNC:7646
GeneCards
NAT2
GenBank Gene Database
D90040
GenBank Protein Database
219412
UniProt Accession
ARY2_HUMAN
HUGO Gene Nomenclature Committee (HGNC)
HGNC:2622
GenAtlas
CYP2C8
GeneCards
CYP2C8
GenBank Gene Database
M17397
Guide to Pharmacology
1325
UniProt Accession
CP2C8_HUMAN
HUGO Gene Nomenclature Committee (HGNC)
HGNC:6834
GenAtlas
MAOB
GeneCards
MAOB
GenBank Gene Database
S62734
GenBank Protein Database
398415
Guide to Pharmacology
2490
UniProt Accession
AOFB_HUMAN
HUGO Gene Nomenclature Committee (HGNC)
HGNC:384
GenAtlas
AKR1C1
GeneCards
AKR1C1
GenBank Gene Database
M86609
GenBank Protein Database
181549
UniProt Accession
AK1C1_HUMAN
HUGO Gene Nomenclature Committee (HGNC)
HGNC:385
GenAtlas
AKR1C2
GeneCards
AKR1C2
GenBank Gene Database
U05598
GenBank Protein Database
531160
UniProt Accession
AK1C2_HUMAN
HUGO Gene Nomenclature Committee (HGNC)
HGNC:2637
GenAtlas
CYP3A4
GeneCards
CYP3A4
GenBank Gene Database
M18907
Guide to Pharmacology
1337
UniProt Accession
CP3A4_HUMAN
HUGO Gene Nomenclature Committee (HGNC)
HGNC:6834
GenAtlas
MAOB
GeneCards
MAOB
GenBank Gene Database
S62734
GenBank Protein Database
398415
Guide to Pharmacology
2490
UniProt Accession
AOFB_HUMAN
HUGO Gene Nomenclature Committee (HGNC)
HGNC:74
GenAtlas
ABCG2
GeneCards
ABCG2
GenBank Gene Database
AF103796
GenBank Protein Database
4185796
Guide to Pharmacology
792
UniProt Accession
ABCG2_HUMAN
HUGO Gene Nomenclature Committee (HGNC)
HGNC:40
GenAtlas
ABCB1
GeneCards
ABCB1
GenBank Gene Database
M14758
GenBank Protein Database
307180
Guide to Pharmacology
768
UniProt Accession
MDR1_HUMAN
Patent information
5 active patents
Source: DrugBank · CC BY-NC 4.0. Patent data sourced from national patent offices. Expiry dates may not reflect extensions, regulatory exclusivity periods, or legal challenges.
DrugBank citations
If you use DrugBank data in your research, please cite the following publications: